ACELYRIN Announces Additional Phase 2 Data And Phase 3 Program Design For Lonigutamab In Thyroid Eye Disease; Patients Demonstrate Potential For Efficacy In Line With Standard Of Care And A More Favorable Safety Profile
ACELYRIN Announces Additional Phase 2 Data And Phase 3 Program Design For Lonigutamab In Thyroid Eye Disease; Patients Demonstrate Potential For Efficacy In Line With Standard Of Care And A More Favorable Safety Profile
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
观察到的甲状腺眼病（TED）患者在皮下使用lonigutamab的全部数据显示其在标准护理下具有潜在疗效，并且安全性更为理想。
Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025
进行了积极的第二阶段FDA会议；第三阶段计划预计在2025年第一季度启动。
Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027
第三阶段的顶线数据预计在2026年下半年发布；现金续航预计到2027年中期。
Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET
将于2025年1月6日（今天）东部时间下午4:30举行电话会议，审查TED的未满足需求、新的第二阶段数据和第三阶段项目设计。
LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease (TED). The Company will host a virtual investor event today, Monday, January 6, 2025 at 4:30 PM ET. To register, click here.
洛杉矶，2025年1月6日（全球新闻通讯） -- ACELYRIN, INC.（纳斯达克：SLRN），一家关注加速转化医学在免疫学领域开发和交付的晚期临床生物制药公司，今日宣布了lonigutamab在甲状腺眼病（TED）中的额外第二阶段数据和第三阶段项目设计。公司将在2025年1月6日（周一）东部时间下午4:30举办虚拟投资者活动。要注册，请点击这里。